Thermo Fisher Scientific’s PPD clinical research business announced a strategic partnership with Datavant to enable privacy‑preserving linkage of de‑identified real‑world data (RWD) across more than 350 partners and 80,000 U.S. hospitals and clinics. The collaboration integrates Datavant’s tokenization to connect EMR data, registries and clinical datasets for biopharma customers. Thermo Fisher said the linkages will support RWD enrichment of randomized trials, registry analytics (PPD CorEvitas), and tailored Evidera evidence generation, improving recruitment, endpoint ascertainment and post‑market surveillance. Executives framed the deal as a step toward scalable, regulatory‑grade RWD connectivity for trial design and safety/effectiveness studies, emphasizing privacy protection and encrypted token workflows.